Combined inhibition of coamplified RTKs is required for response.

Slides:



Advertisements
Similar presentations
B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT
Advertisements

GM-CSF induces tumor cell EMT and stemness.
A, baseline and 4-week PET scan from patient 2 (MET c
MEL23 and MEL24 inhibit Mdm2 and p53 ubiquitination in cells.
AKT dependence of ovarian cancer cell lines.
Pioglitazone inhibits aromatase expression in human preadipocytes.
Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Interfering with HMGA2 expression blocks transformation in metastatic lung cancer cells. Interfering with HMGA2 expression blocks transformation in metastatic.
BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.
Leto et al., Supplementary Figure S3
A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.
Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.
Mechanism of piperlongumine induced Sp downregulation.
RXRa serves as a carrier for TR3 translocation initiated by 9-cis retinoic acid. RXRa serves as a carrier for TR3 translocation initiated by 9-cis retinoic.
Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.
Effects of Z-FA-FMK on SMN protein expression in type II SMA patient fibroblast cells (GM22592). Effects of Z-FA-FMK on SMN protein expression in type.
(fold of TGF-β1 response)
IL-6 inhibits insulin-induced formation of p85/IRS-1 complexes.
The sesquiterpene lactone PN up-regulates MDM2 and p53 proteins.
PTB-independent ShcA pools require Src to promote mammary tumorigenesis. PTB-independent ShcA pools require Src to promote mammary tumorigenesis. A, Src.
PTENP1 sensitizes renal cancer cells to chemotherapy.
The role of p53 in H2O2-mediated cell death of hOGG1-deficient H1299 lung carcinoma p53 null cells. The role of p53 in H2O2-mediated cell death of hOGG1-deficient.
Identification of NSC as a FADD-kinase inhibitor.
BME treatment increases granzyme B expression in NK 3.3 cells.
Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. A.
Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.
A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.
A, TSG-6 staining in TRAMP tissue and TRAMP cell lines.
Effect of TLR-4 ligation with LPS on NF-κB activation in EOC cells: (A) MyD88+ and (B) MyD88− EOC cells were treated with 10 μg/mL LPS for 1, 2, and 4.
Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.
Src expression in a panel of human TCC cell lines.
FACS analyses of the inhibitory effect induced by mixed docetaxel, gefitinib, and cyclopamine on EGF plus SHHNp–stimulated PC3 cells. FACS analyses of.
Drug interaction signatures for GIST and benign osteoma cell lines representing all combinatorial data compiled in a 9 × 9 drug matrix. Drug interaction.
Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.
Pirh2 represses p73-dependent transactivation.
GM-CSF is required for CA-MSC–induced tumor metastasis.
NKT cell recognition of CD1d1 molecules is inhibited by treatment with ascites. NKT cell recognition of CD1d1 molecules is inhibited by treatment with.
KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.
Characterization of DNA-PK and PARP-1 levels and activities in the cell lines studied. Characterization of DNA-PK and PARP-1 levels and activities in the.
HMQ1611 inhibited breast tumor growth in mice.
Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.
Tivantinib does not inhibit MET function.
Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.
FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung cancer cell lines. FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung.
MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.
Pdcd4 expression inhibits AP-1 transactivation.
Change in FES uptake in the tumor during fulvestrant treatment.
Frequent coamplification of RTKs in MET-amplified EGC
SAHA blocks IR-induced increase of RAD51 protein in MM cells.
SW620 xenografts treated with combination siKRAS+siPIK3CA/B.
The effects of AZD1775 and olaparib on DNA damage response signaling.
Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.
Increased expression of angiogenic factors and inflammatory cytokines in mice exposed to hypoxia. Increased expression of angiogenic factors and inflammatory.
Effect of bevacizumab on the proliferation of A2780 cells.
BEZ235 induces accelerated senescence after radiation (IR) in vitro.
MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.
Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.
Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.
Effect of dexamethasone on PCDGF/GP88 mRNA and protein expressions and effect of PCDGF/GP88 on dexamethasone-induced cell death. Effect of dexamethasone.
CPGL is a growth suppressor in pancreatic cancer cell lines.
Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.
MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.
Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.
Effect of SFN on the total activity and protein expression of HDACs in JB6 P+ cells. Effect of SFN on the total activity and protein expression of HDACs.
TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3 pathway. TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3.
MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.
I3C reduces the level of Cdc25A protein in breast cancer cells.
Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.
SCLC in CMV TKO mice arises from an alternative cell of origin.
Presentation transcript:

Combined inhibition of coamplified RTKs is required for response. Combined inhibition of coamplified RTKs is required for response. A, OE33 cells were treated with the indicated concentrations of crizotinib alone, lapatinib alone, or both drugs in combination for 72 hours, and cell titer was determined. B, Western blot of OE33 cells treated with the indicated concentrations of crizotinib, lapatinib, or both drugs in combination for 24 hours. C, SNU638 cells exogenously expressing HER2, MET, or empty vector control were treated with the indicated concentrations of drug(s) for 72 hours, and cell titer was determined. D, the same cells from C were treated with the indicated concentrations of drug for 24 hours, and Western blotting was performed with the indicated antibodies. E, FISH images showing >25-fold amplification of both MET and HER2 in the same tumor cells from Patient #3. F, PET images from Patient #3 obtained before treatment and after 2 months of therapy with combined MET/HER2 inhibition. Eunice L. Kwak et al. Cancer Discov 2015;5:1271-1281 ©2015 by American Association for Cancer Research